A Phase ll, Randomized, Double-blind, Placebo-controlled Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis

Trial Profile

A Phase ll, Randomized, Double-blind, Placebo-controlled Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs IMM 124E (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Immuron
  • Most Recent Events

    • 13 Mar 2018 According to an Immuron media release, the company is planning to share data from this trial in roadshow to investment institutions, analysts and shareholders.
    • 07 Mar 2018 Topline results presented in the Immuron Media Release.
    • 09 Nov 2017 According to an Immuron media release, Last Patient Last Visit has been completed and data due in the first quarter of next year (Q1 CY2018).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top